The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

1 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this three-part series, Katy Beckermann, MD, PhD, of Tennessee Oncology, speaks with David Braun, MD, PhD, of Yale Cancer Center, on his Nature publication on a neoantigen vaccine that has demonstrated the ability to generate antitumor immunity in RCC.

In this segment, they highlight the logistical and biological considerations that influenced the trial design, the complexities of manufacturing and regulatory approval, the critical role of a multidisciplinary team in antigen selection and peptide synthesis, and the remarkable commitment of patients who underwent extensive procedures to advance the science, all while emphasizing the potential of such vaccines in the minimal residual disease setting.
Category
Oncology
Be the first to comment

Up Next